- Home
- CRWD vs VRTX Comparison
CRWD vs VRTX Comparison
Compare CRWD & VRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRWD
- VRTX
- Stock Information
- Founded
- CRWD 2011
- VRTX 1989
- Country
- CRWD United States
- VRTX United States
- Employees
- CRWD N/A
- VRTX N/A
- Industry
- CRWD EDP Services
- VRTX EDP Services
- Sector
- CRWD Technology
- VRTX Technology
- Exchange
- CRWD Nasdaq
- VRTX Nasdaq
- Market Cap
- CRWD 126.0B
- VRTX 115.6B
- IPO Year
- CRWD 2019
- VRTX 1991
- Fundamental
- Price
- CRWD $471.23
- VRTX $469.47
- Analyst Decision
- CRWD Buy
- VRTX Buy
- Analyst Count
- CRWD 49
- VRTX 25
- Target Price
- CRWD $454.33
- VRTX $509.00
- AVG Volume (30 Days)
- CRWD 2.9M
- VRTX 1.1M
- Earning Date
- CRWD 08-27-2025
- VRTX 08-04-2025
- Dividend Yield
- CRWD N/A
- VRTX N/A
- EPS Growth
- CRWD N/A
- VRTX N/A
- EPS
- CRWD N/A
- VRTX N/A
- Revenue
- CRWD $4,136,022,000.00
- VRTX $11,099,700,000.00
- Revenue This Year
- CRWD $23.38
- VRTX $10.43
- Revenue Next Year
- CRWD $21.85
- VRTX $10.81
- P/E Ratio
- CRWD N/A
- VRTX N/A
- Revenue Growth
- CRWD 25.94
- VRTX 8.98
- 52 Week Low
- CRWD $200.81
- VRTX $377.85
- 52 Week High
- CRWD $517.98
- VRTX $519.88
- Technical
- Relative Strength Index (RSI)
- CRWD 45.17
- VRTX 55.74
- Support Level
- CRWD $465.76
- VRTX $456.83
- Resistance Level
- CRWD $490.04
- VRTX $472.22
- Average True Range (ATR)
- CRWD 12.98
- VRTX 8.88
- MACD
- CRWD -4.21
- VRTX -0.30
- Stochastic Oscillator
- CRWD 14.19
- VRTX 54.21
About CRWD CrowdStrike Holdings Inc.
CrowdStrike is a cloud-based cybersecurity company specializing in next-generation security verticals such as endpoint, cloud workload, identity, and security operations. CrowdStrike's primary offering is its Falcon platform that offers a proverbial single pane of glass for an enterprise to detect and respond to security threats attacking its IT infrastructure. The Texas-based firm was founded in 2011 and went public in 2019.
About VRTX Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease. Additionally, Vertex is evaluating small-molecule inhibitors targeting acute and chronic pain using nonopioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.